SCHEMBL16809161

SCHEMBL16809161

Cc1cc(-c2cccc(C#N)c2)ccc1N

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.59
CYP3A4 P08684 2/20 0.59
TSHR P16473 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
PGR P06401 6/20 0.49
AR P10275 1/20 0.49
MAP4K4 O95819 2/20 0.49
CLK4 Q9HAZ1 2/20 0.46
ADORA2A P29274 2/20 0.46
XDH P47989 2/20 0.45
SLC22A12 Q96S37 1/20 0.45
ADORA1 P30542 1/20 0.44
CYP1A2 P05177 1/20 0.43
BACE1 P56817 1/20 0.42
PTPN5 P54829 1/20 0.42
GSK3A P49840 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21388680 0.84 ALDH1A1 (0.65) ALDH1A1CYP3A4TSHRTDP1PGR
SCHEMBL5952080 0.84 MEN1 (0.54) TDP1PGRARMAP4K4CLK4
SCHEMBL10248395 0.79 HSD17B1 (0.59) CYP3A4PGRARCLK4XDH
SCHEMBL5844552 0.79 XDH (0.60) CYP3A4PGRARMAP4K4CLK4
SCHEMBL627108 0.79 CYP3A4 (0.50) ALDH1A1CYP3A4TSHRTDP1PGR
SCHEMBL2154026 0.79 CLK4 (0.65) TSHRPGRMAP4K4CLK4XDH
Orthotolidine SCHEMBL2812115 0.79 CYP3A4 (0.94) ALDH1A1CYP3A4TSHRTDP1
SCHEMBL1143498 0.78 MAP4K4 (0.54) CYP3A4TDP1PGRMAP4K4CLK4
SCHEMBL16905206 0.78 CLK4 (0.52) PGRARMAP4K4CLK4ADORA2A
SCHEMBL4443914 0.78 ALDH1A1 (0.52) ALDH1A1CYP3A4PGRARMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170305897-A1 BENZIMIDAZOLE-PROLINE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2017-10-26 US disclosed
US-9732075-B2 Benzimidazole-proline derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2017-08-15 US disclosed
EP-2855453-B1 BENZIMIDAZOLE-PROLINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2016-12-07 EP disclosed
US-20150166527-A1 BENZIMIDAZOLE-PROLINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2015-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166527-A1 BENZIMIDAZOLE-PROLINE DERIVATIVES HCRTR1, HCRTR2, NPY1R ALDH1A1 519/4885CYP3A4 1012/4885TSHR 342/4885
US-20170305897-A1 BENZIMIDAZOLE-PROLINE DERIVATIVES HCRTR1, HCRTR2, NPY1R ALDH1A1 604/4885CYP3A4 1106/4885TSHR 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.